Antismooth Muscle and Antiactin Antibodies Are Indirect Markers of Histological and Biochemical Activity of Autoimmune Hepatitis

Imagem de Miniatura
Arquivos
art_PORTA_Antismooth_Muscle_and_Antiactin_Antibodies_Are_Indirect_Markers_2014.PDF (376.55 KB)
Citações na Scopus
78
Tipo de produção
article
Data de publicação
2014
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY-BLACKWELL
Autores
COUTO, Claudia A.
BITTENCOURT, Paulo L.
GUARDIA, Bianca D.
Citação
HEPATOLOGY, v.59, n.2, p.592-600, 2014
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Reactivity and titers of autoantibodies vary during the course of autoimmune hepatitis (AIH), and some autoantibodies have been associated with disease activity and adverse outcomes after treatment. The aim of this study was to assess the autoantibody behavior in AIH and its significance as predictors of biochemical and histological remission. A total of 117 patients with AIH (mean age 18.6 [4-69] years) were evaluated and tested for autoantibodies at disease onset and successively (mean 3.2 [2-6] times) after a mean follow-up evaluation of 70 [20-185] months. Antismooth muscle (ASMA), antiliver kidney microsome type 1 (anti-LKM1), antiliver cytosol type 1 (anti-LC1), antimitochondrial, antinuclear (ANA), and antiactin antibodies (AAA) were determined at disease onset and 379 other times during the follow-up evaluation through indirect immunofluorescence in rodent tissues, HEp-2 cells, and human fibroblasts. Anti-SLA/LP were assessed 45 times in the follow-up evaluation of 19 patients using enzyme-linked immunosorbent assay (ELISA). Upon admission, AIH types 1 and 2 were observed in 95 and 17 patients, respectively. Five subjects had AIH with anti-SLA/LP as the sole markers. Patients initially negative for AAA did not develop these antibodies thereafter. ANA were detected de novo in six and three subjects with AIH types 1 and 2, respectively. After treatment, only ASMA (>1:80) and AAA (>1:40) were significantly associated with biochemical (76.9% and 79.8%) and histological features (100% and 100%) of disease activity (P<0.001). Conclusion: With the exception of ANA, the autoantibody profile does not markedly vary in the course of AIH. The persistence of high titers of ASMA and/or AAA in patients with AIH is associated with disease activity. (Hepatology 2014;59:592-600)
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/5383
Referências
  1. Alvarez F., 1999, Journal of Hepatology, V31, P929, DOI 10.1016/S0168-8278(99)80297-9
  2. ALVAREZ F, 1985, J EXP MED, V161, P1231, DOI 10.1084/jem.161.5.1231
  3. Baeres M, 2002, GUT, V51, P259, DOI 10.1136/gut.51.2.259
  4. Ballot E, 2000, J HEPATOL, V33, P208, DOI 10.1016/S0168-8278(00)80361-X
  5. Bittencourt PL, 1999, AM J GASTROENTEROL, V94, P1906
  6. Cancado ELR, 2001, J AUTOIMMUN, V17, P223, DOI 10.1006/jaut.2001.0540
  7. Cassani F, 1997, HEPATOLOGY, V26, P561, DOI 10.1002/hep.510260305
  8. Czaja AJ, 1996, HEPATOLOGY, V24, P1068
  9. Czaja AJ, 2002, HEPATOLOGY, V36, P479, DOI 10.1053/jhep.2002.34944
  10. Czaja AJ, 2002, J HEPATOL, V37, P302, DOI 10.1016/S0168-8278(02)00182-4
  11. Czaja AJ, 2002, AM J GASTROENTEROL, V97, P413
  12. Czaja AJ, 1999, J HEPATOL, V30, P394, DOI 10.1016/S0168-8278(99)80096-8
  13. DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1016/0270-9139(94)90250-X
  14. Gayotto LCC, 2000, GED, V19, P137
  15. Granito A, 2006, J CLIN PATHOL, V59, P280, DOI 10.1136/jcp.2005.027367
  16. Gregorio GV, 2001, HEPATOLOGY, V33, P544, DOI 10.1053/jhep.2001.22131
  17. Gregorio GV, 2002, AUTOIMMUNITY, V35, P515, DOI 10.1080/0891693021000056721
  18. HOMBERG JC, 1987, HEPATOLOGY, V7, P1333, DOI 10.1002/hep.1840070626
  19. JOHNSON PJ, 1993, HEPATOLOGY, V18, P998, DOI 10.1002/hep.1840180435
  20. KRAWITT EL, 1994, AM J MED, V96, P23
  21. Krawitt EL, 2006, NEW ENGL J MED, V354, P54, DOI 10.1056/NEJMra050408
  22. Ma Y, 2002, HEPATOLOGY, V35, P658, DOI 10.1053/jhep.2002.32092
  23. MANNS M, 1987, LANCET, V1, P292
  24. Manns MP, 2010, HEPATOLOGY, V51, P2193, DOI 10.1002/hep.23584
  25. Mehendiratta V, 2009, CLIN GASTROENTEROL H, V7, P98, DOI 10.1016/j.cgh.2008.08.043
  26. Miyake Y, 2009, HEPATOL RES, V39, P241, DOI 10.1111/j.1872-034X.2008.00454.x
  27. Muratori L, 1998, GUT, V42, P721
  28. NORBERG R, 1979, EUR J BIOCHEM, V100, P575, DOI 10.1111/j.1432-1033.1979.tb04204.x
  29. Vergani D, 2004, J HEPATOL, V41, P677, DOI 10.1016/j.jhep.2004.08.002
  30. Vuppalanchi R, 2012, HEPATOL INT, V6, P379, DOI 10.1007/s12072-011-9277-8

Coleções
Artigos e Materiais de Revistas Científicas - FM/MGT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/ICr
Artigos e Materiais de Revistas Científicas - LIM/06
Artigos e Materiais de Revistas Científicas - LIM/07
Artigos e Materiais de Revistas Científicas - ODS/03